


SD-6

Cat. No.:	HY-149212
CAS No.:	744206-31-3
Molecular Formula:	C ₂₀ H ₂₂ N ₄ OS
Molecular Weight:	366.48
Target:	Cholinesterase (ChE)
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SD-6 is an orally active inhibitor of hAChE and hBCHE with IC ₅₀ values of 0.907 μM and 1.579 μM, respectively. SD-6 has excellent blood-brain barrier (BBB) permeability and no neurotoxicity, which can be used for research on Alzheimer's disease ^[1] .									
IC₅₀ & Target	hAChE 0.907 μM (IC ₅₀)	hBCHE 1.579 μM (IC ₅₀)								
In Vitro	<p>SD-6 (5-80 μM; 24 h) has neuroprotective effects in SH-SY5Y cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SH-SY5Y cells.</td> </tr> <tr> <td>Concentration:</td> <td>5, 10, 20, 40 or 80 μM.</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h.</td> </tr> <tr> <td>Result:</td> <td>Exhibited toxicity to differentiated SH-SY5Y cell lines and has a protective effect on undifferentiated SH-SY5Y cell lines.</td> </tr> </table>		Cell Line:	SH-SY5Y cells.	Concentration:	5, 10, 20, 40 or 80 μM.	Incubation Time:	24 h.	Result:	Exhibited toxicity to differentiated SH-SY5Y cell lines and has a protective effect on undifferentiated SH-SY5Y cell lines.
Cell Line:	SH-SY5Y cells.									
Concentration:	5, 10, 20, 40 or 80 μM.									
Incubation Time:	24 h.									
Result:	Exhibited toxicity to differentiated SH-SY5Y cell lines and has a protective effect on undifferentiated SH-SY5Y cell lines.									
In Vivo	<p>SD-6 (100, 300 and 500 mg/kg; p.o.; single dose) has no toxic effect on nonpregnant female Wistar rats^[1]. SD-6 (2.5, 5 and 10 mg/kg; p.o.; 3 times a day for 7 days) improves cognitive and memory deficits induced by Scopolamine (HY-N0296) in male Wistar rats^[1]. SD-6 (2.5, 5 and 10 mg/kg; p.o.; single dose) significantly improves the abnormalities induced by Scopolamine in rats and promotes the normalization of biochemical indicators^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>10–11 weeks nonpregnant female Wistar rats (220–280 g)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>100, 300 and 500 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; single dose.</td> </tr> </table>		Animal Model:	10–11 weeks nonpregnant female Wistar rats (220–280 g) ^[1] .	Dosage:	100, 300 and 500 mg/kg.	Administration:	Oral gavage; single dose.		
Animal Model:	10–11 weeks nonpregnant female Wistar rats (220–280 g) ^[1] .									
Dosage:	100, 300 and 500 mg/kg.									
Administration:	Oral gavage; single dose.									

Result:	Showed safety and tolerability.
Animal Model:	10–11 weeks male Wistar rats (220–280 g) ^[1] .
Dosage:	2.5–5–10 mg/kg.
Administration:	Oral gavage; 3 times a day for 7 days or single dose.
Result:	Had the function of repairing cognitive and memory deficits. Reduced the level of AChE and malonaldehyde (MDA), increased the level of acetylcholine, superoxide dismutase (SOD), glutathione (GSH) and catalase.

REFERENCES

[1]. Waiker DK, et al. Development and Evaluation of Some Molecular Hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1,3,4-oxadiazol-2-yl)thio) as Multifunctional Agents to Combat Alzheimer's Disease. ACS Omega. 2023 Mar 2;8(10):9394-9414.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA